Lucira Health

Lucira Health, Inc. provides DNA testing services for medical, forensics, chemical, industrial, and agricultural applications. The company was founded by Debkishore Mitra, John Robert Waldeisen and Benjamin Ross in 2013 and is headquartered in Emeryville, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand.

EMERYVILLE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report second quarter 2022 financial results on, Monday, August 15, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Lucira Health to Announce Second Quarter 2022 Financial Results

Lucira Health, Inc. (NASDAQ:LHDX ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Louisa Smith - Gilmartin Group, IR Erik Engelson - President, CEO Dan George - CFO Conference Call Participants Brian Weinstein - William Blair Rahul Rakhit - LifeSci Capital Operator Good afternoon, ladies and gentlemen. And welcome to the Lucira Health First Quarter Earnings Conference Call.

Lucira Health, Inc. (LHDX) CEO Erik Engelson on Q1 2022 Results - Earnings Call Transcript

EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results and provided business updates for the first quarter ended March 31, 2022.

Lucira Health Announces First Quarter 2022 Results and Business Update

Lucira Health Inc. LHDX, -6.02% said Thursday it has filed for Food and Drug Administration authorization for its first-of-its-kind COVID-19 & flu at-home molecular test. The medical tech company, which went public in February of 2021, specializes in single-use test kits for respiratory diseases.

Lucira Health files for FDA authorization of first COVID-19 & flu at-home molecular test

This first ever at-home COVID-19 and flu test is designed to allow individuals to differentiate between the infections and seek appropriate treatment within 30 minutes from home This first ever at-home COVID-19 and flu test is designed to allow individuals to differentiate between the infections and seek appropriate treatment within 30 minutes from home

Lucira Files for Authorization of First-of-its-Kind COVID-19 & Flu At-Home Molecular Test

EMERYVILLE, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will participate in the Bank of America 2022 Healthcare Conference on May 11th, 2022, at 11:00pm ET.

Lucira Health to Participate in Bank of America 2022 Healthcare Conference

EMERYVILLE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report first quarter 2022 financial results on Thursday, May 12, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Lucira Health to Announce First Quarter 2022 Financial Results

Buckle

BRP Inc

Lovesac Company

Forget undervalued stocks, play these top-ranked stocks (BKE, LHDX, DOOO, LOVE, KTB) with rising P/E.

Grab Market Momentum With 5 Top Rising P/E Stocks

Lucira is the official COVID-19 test provider of USA Boxing athletes and staff and will commit $5 of support to the organization for each test purchased by fans EMERYVILLE, Calif. , April 21, 2022 /PRNewswire/ -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focusing on the development and commercialization of transformative and innovative infectious disease tests, announces its first-ever partnership with USA Boxing as the official COVID-19 test provider for the 2022 season.

LUCIRA HEALTH AND USA BOXING ANNOUNCE EXCLUSIVE PARTNERSHIP FOR THE 2022 SEASON

EMERYVILLE, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that on April 6, 2022, the Board of Directors of Lucira granted inducement awards consisting of 20,825 restricted stock units (“RSUs”) to three new employees under Lucira's 2022 Inducement Plan. The Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Lucira Health Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Lucira Health (LHDX).

Looking for a Growth Stock? Why It is Time to Focus on Lucira Health (LHDX)

New York, New York--(Newsfile Corp. - April 1, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Lucira Health, Inc. (NASDAQ: LHDX) resulting from allegations that Lucira may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Lucira securities you may be entitled to compensation without payment of any out of pocket fees or costs through...

LHDX INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Lucira Health, Inc. Investors with Losses to Inquire About Class Action Investigation - LHDX

COVID-19 Comes to Isolated Pacific Island of Tonga  And Cases Soar After Volcanic Eruption and Tsunami EMERYVILLE, Calif. , March 31, 2022 /PRNewswire/ -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, donated 2,000 Lucira™ Check-It COVID-19 tests, a rapid at-home test with PCR-quality accuracy, for Tonga humanitarian efforts after the eruption of the Hunga Tonga-Hunga Ha'apai volcano in January 2022.

Lucira Donates Rapid Molecular At-Home COVID-19 Test Kits to Protect the Safety of Tonga Red Cross Society Workers

Lucira's molecular test provides PCR-quality results in 30 minutes in a simple single-use test Lucira was the first at-home COVID-19 test authorized in Canada and has been used in public health programs and for safe travel EMERYVILLE, Calif. , March 24, 2022 /PRNewswire/ -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, announced that its Lucira™ Check-It COVID-19 test can now be purchased directly by Canadian consumers, businesses, and healthcare providers, available at www.checkit.lucirahealth.ca.

Lucira Health's PCR-Quality At-Home COVID-19 Test Now Available Direct to Consumers in Canada

Lucira Health, Inc. (LHDX) CEO Erik Engelson on Q4 2021 Results - Earnings Call Transcript

EMERYVILLE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Lucira Health Announces Fourth Quarter and Full Year 2021 Results and Reaffirms 2022 Financial Outlook

EMERYVILLE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”) (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report fourth quarter 2021 financial results on, Thursday, March 10, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Lucira Health to Announce Fourth Quarter 2021 Financial Results

Lucira Health Inc LHDX has entered into a debt facility of up to $80 million with Hercules Capital and Silicon Valley Bank.  Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Lucira Health Shares Fall After Announcing Debt Facility Of $80M

EMERYVILLE, Calif., Feb. 3, 2022 /PRNewswire/ -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focusing on the development and commercialization of transformative and innovative infectious disease test kits, announced more than two million Lucira ™ Check-It COVID-19 tests, a rapid at-home test with PCR-quality accuracy, are available on Amazon.com.

Lucira™ Health Commits 2 Million At-Home Molecular COVID-19 Test Kits on Amazon

The stock price of Lucira Health Inc (NASDAQ: LHDX) increased by 15.62% in the most recent trading session. These are the details.

Lucira Health Stock (LHDX): Why The Price Jumped

EMERYVILLE, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, announced that its Lucira™ Check-It PCR-Quality, At-Home Molecular COVID-19 Test is now available in the Optum Store (store.optum.com).

Lucira™ Check-It PCR-Quality, At-Home Molecular COVID-19 Test Now Available in the Optum Store

EMERYVILLE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced preliminary revenue results for the fourth quarter and full year 2021.

Lucira Health Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2021 and Provides Business Update

NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lucira Health, Inc. ("Lucira" or the "Company") (NASDAQ: LHDX). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lucira Health, Inc. - LHDX

EMERYVILLE, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, announced a new distribution agreement for at least 600,000 tests in 2022 with Co-Defend, Inc. and Co-Protect, LLC, leading providers of customized health, safety, and wellness solutions.

Lucira Health and Co-Defend/Co-Protect Announce Expanded Partnership for 2022

EMERYVILLE, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, announced a new agreement with Switch Health Solutions Inc. ("Switch Health") to increase Canadians' access to at-home molecular COVID-19 tests as Omicron cases surge. Lucira will provide more than 2 million at-home COVID-19 test kits in 2022 as part of the deal.

News for Lucira Health Stock (LHDX)